



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
David J. Yang *et al.*

Serial No.: 10/732,919

Filed: December 10, 2003

For: N2S2 CHELATE-TARGETING LIGAND
CONJUGATES

Group Art Unit: 1616

Examiner: Unknown

Atty. Dkt. No.: UTSC:841US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

May 26, 2004

Date

David L. Parker

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:841US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'David L. Parker', written over the words 'Respectfully submitted,'.

David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 26, 2004

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:841US

Serial No.

10/732,919

List of Patents and Publications for Applicant's

Applicant

David J. Yang *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

December 10, 2003

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|----------|--------------------------|-------|-----------|---------------------|
| | A1 | 2001/0041189 | 11/15/01 | Xu | 424 | 488 | 4/13/99 |
| | A2 | 2001/0034363 | 10/25/01 | Li <i>et al.</i> | 514 | 449 | 3/30/98 |
| | A3 | 4,418,068 | 11/29/83 | Jones | 424 | 267 | 12/16/81 |
| | A4 | 4,507,466 | 3/26/85 | Tomalia <i>et al.</i> | 528 | 332 | 1/07/83 |
| | A5 | 4,558,120 | 12/10/85 | Tomalia <i>et al.</i> | 528 | 363 | 12/27/83 |
| | A6 | 4,568,737 | 2/04/86 | Tomalia <i>et al.</i> | 528 | 332 | 8/17/84 |
| | A7 | 4,587,329 | 5/06/86 | Tomalia <i>et al.</i> | 528 | 363 | 7/19/85 |
| | A8 | 4,631,337 | 12/23/86 | Tomalia <i>et al.</i> | 528 | 391 | 7/11/85 |
| | A9 | 4,694,064 | 9/15/87 | Tomalia <i>et al.</i> | 528 | 332 | 2/28/86 |
| | A10 | 4,713,975 | 12/22/87 | Tomalia <i>et al.</i> | 73 | 864.8 | 5/30/86 |
| | A11 | 4,732,863 | 3/22/88 | Tomasi <i>et al.</i> | 436 | 547 | 12/31/84 |
| | A12 | 4,737,550 | 4/12/88 | Tomalia | 525 | 419 | 12/08/86 |
| | A13 | 4,857,599 | 8/15/89 | Tomalia <i>et al.</i> | 525 | 259 | 2/08/88 |
| | A14 | 4,871,779 | 10/03/89 | Killat <i>et al.</i> | 521 | 28 | 12/23/85 |
| | A15 | 4,988,496 | 02/29/91 | Srinivasan <i>et al.</i> | 424 | 1.53 | 05/31/88 |
| | A16 | 5,087,616 | 2/11/92 | Myers <i>et al.</i> | 514 | 21 | 8/06/87 |
| | A17 | 5,108,921 | 04/28/92 | Low <i>et al.</i> | 435 | 240.1 | 03/28/90 |
| | A18 | 5,164,294 | 11/17/92 | Skold <i>et al.</i> | 435 | 7.5 | 7/07/89 |
| | A19 | 5,268,163 | 12/07/93 | Verbruggen | 424 | 1.1 | 4/10/91 |
| | A20 | 5,279,811 | 1/18/94 | Bergstein <i>et al.</i> | 424 | 1.65 | 1/26/88 |
| | A21 | 5,412,072 | 5/02/95 | Sakurai <i>et al.</i> | 530 | 322 | 3/21/90 |
| | A22 | 5,416,016 | 05/16/95 | Low <i>et al.</i> | 435 | 240.1 | 03/13/92 |
| | A23 | 5,517,993 | 5/21/96 | Unger and Wu | 128 | 653.4 | 6/07/95 |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

| | | |
|---|---|--------------------------------|
| Form PTO-1449 (modified) | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | Applicant David J. Yang <i>et al.</i> | |
| | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> |

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|----------|-------------------------------|-------|-----------|---------------------|
| | A24 | 5,534,241 | 7/09/96 | Torchilin <i>et al.</i> | 424 | 9.321 | 7/23/93 |
| | A25 | 5,605,671 | 2/25/97 | Lyle <i>et al.</i> | 424 | 1.41 | 4/29/94 |
| | A26 | 5,635,382 | 06/03/97 | Low <i>et al.</i> | 435 | 172.3 | 12/05/94 |
| | A27 | 5,635,603 | 6/03/97 | Hansen <i>et al.</i> | 530 | 391.5 | 12/05/94 |
| | A28 | 5,670,132 | 9/23/97 | Griffiths <i>et al.</i> | 424 | 1.11 | 9/20/94 |
| | A29 | 5,688,488 | 11/18/97 | Low <i>et al.</i> | 424 | 1.69 | 05/16/95 |
| | A30 | 5,730,968 | 3/24/98 | Butterfield <i>et al.</i> | 424 | 78.37 | 3/31/94 |
| | A31 | 5,820,847 | 10/13/98 | Low <i>et al.</i> | 424 | 9.1 | 01/15/97 |
| | A32 | 5,830,431 | 11/03/98 | Srinivasan <i>et al.</i> | 424 | 1.69 | 6/07/95 |
| | A33 | 5,908,777 | 6/01/99 | Lee <i>et al.</i> | 435 | 320.1 | 3/23/95 |
| | A34 | 5,951,964 | 9/14/99 | Dean <i>et al.</i> | 424 | 1.69 | 6/4/93 |
| | A35 | 5,955,053 | 9/21/99 | Marzilli <i>et al.</i> | 424 | 1.11 | 5/6/96 |
| | A36 | 5,977,163 | 11/2/99 | Li <i>et al.</i> | 514 | 449 | 3/11/97 |
| | A37 | 5,986,074 | 11/16/99 | Marzilli <i>et al.</i> | 534 | 14 | 12/18/97 |
| | A38 | 6,071,533 | 6/06/00 | Papahadjopoulos <i>et al.</i> | 424 | 450 | 11/17/95 |
| | A39 | 6,083,741 | 7/04/00 | Hart <i>et al.</i> | 435 | 320.1 | 11/17/95 |
| | A40 | 6,113,946 | 9/05/00 | Szoka, Jr. <i>et al.</i> | 424 | 486 | 6/06/95 |
| | A41 | 6,197,278 | 3/6/01 | Blankenberg <i>et al.</i> | 424 | 1.69 | 4/29/98 |
| | A42 | 6,251,866 | 6/26/01 | Prakash <i>et al.</i> | 514 | 17 | 8/04/98 |
| | A43 | 6,262,107 | 7/17/01 | Li <i>et al.</i> | 514 | 449 | 7/01/99 |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Class | Sub Class | Translation Yes/No |
|-------------|-----------|-----------------|----------|---------|-------|-----------|--------------------|
| | B1 | WO 00/53233 | 9/14/00 | PCT | | | English |
| | B2 | WO 00/61788 | 10/19/00 | PCT | | | English |
| | B3 | WO 01/80906 | 11/01/01 | PCT | | | English |
| | B4 | WO 01/91807 | 12/06/01 | PCT | | | English |
| | B5 | WO 91/16076 | 10/31/91 | PCT | | | English |
| | B6 | WO 95/28966 | 11/02/95 | PCT | | | English |
| | B7 | WO 97/33552 | 9/18/97 | PCT | | | English |
| | B8 | WO 99/39748 | 8/12/99 | PCT | | | English |
| | B9 | WO 99/49901 | 10/07/99 | PCT | | | English |
| | B10 | WO 99/61512 | 12/02/99 | PCT | | | English |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C1 | Abrams <i>et al.</i> , "Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats," <i>J. Nucl. Med.</i> , 31:2022-2028, 1990. |
| | C2 | Alauddin and Conti, "Synthesis and preliminary evaluation of 9-(4-{[18F]-Fluoro-3-Hydroxymethylbutyl}guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy," <i>Nucl. Med. Biol.</i> , 25:175-180, 1998. |
| | C3 | Alauddin <i>et al.</i> , "9-[(3-18F)-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET," <i>Nucl. Med. Biol.</i> , 23:787-792, 1996. |
| | C4 | Alauddin <i>et al.</i> , "Evaluation of 9-[(3-18F)-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as probe for PET imaging of gene incorporation and expression in tumors," <i>Nucl. Med. Biol.</i> , 26:371-376, 1999. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|---|---------------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C5 | Alauddin <i>et al.</i> , "Receptor mediated uptake of a radiolabeled contrast agent sensitive to β -galactosidase activity," <i>Nucl. Med. Biol.</i> , 30:261-265, 2002. |
| | C6 | Alper <i>et al.</i> , "Assessment of renal functional changes following transurethral prostatectomy using tc-99m ethylenedicycysteine," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1292, 1996. |
| | C7 | Anderson <i>et al.</i> , "N,N'-ethylene-di-l-cysteine (ec) complexes of ga(III) and In (III): molecular modeling, thermodynamic stability and in vivo studies," <i>Nucl. Med. Biol.</i> , 22:165-173, 1995. |
| | C8 | Anderson <i>et al.</i> , "Radiometal-labeled agents (non-technetium) for diagnostic imaging," <i>Chem. Rev.</i> , 99:2219-2234, 1999. |
| | C9 | Antony, "Folate receptors," <i>Ann. Rev.</i> , 16:501-521, 1996. |
| | C10 | Aoi <i>et al.</i> , "Globular carbohydrate macromolecule 'sugar balls' 3. 'radical-growth polymerization' of sugar-substituted α -amino acid N-carboxyanhydrides (glycoNCAs) with a dendritic initiator," <i>Tetrahedron, Elsevier Science Publishers</i> , 53(45):15415-15427, 1997. |
| | C11 | Appelbaum <i>et al.</i> , "The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia," <i>Transplantation</i> , 54(5):829-833, 1992. |
| | C12 | Baidoo and Lever, "Evaluation of a diaminedithiol-based bifunctional chelate for labeling small molecules with ^{99m}Tc ," <i>Technetium and Rhenium in Chemistry and Nuclear Medicine</i> , 1990. |
| | C13 | Baidoo <i>et al.</i> , "Synthesis of a new diaminedithiol bifunctional chelate for the preparation of neutral technetium complexes," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 414, 1990. |
| | C14 | Bajorin <i>et al.</i> , <i>Proc. Annu. Meet. Am. Soc. Clin. Oncol.</i> , 7:250, A967, 1988. |
| | C15 | Bakker <i>et al.</i> , "Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals," <i>J. Nucl. Med.</i> , 31:1501-1509, 1990. |
| | C16 | Bar-Sever <i>et al.</i> , "Comparison of living related donor and recipient renograms in predicting the early posttransplantation course," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1305, 1996. |
| | C17 | Baselga <i>et al.</i> , "Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin," <i>J. Clinical Oncology</i> , 18(4):904-914, 2000. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C18 | Baselga <i>et al.</i> , "Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/new overexpressing human breast cancer xenografts," <i>Cancer Research</i> , 58:2825-2831, 1998. |
| | C19 | Becker <i>et al.</i> , "Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody," <i>American Journal of Pathology</i> , 155(6):1803-1809. |
| | C20 | Benns <i>et al.</i> , "Tailoring new gene delivery designs for specific targets," <i>Journal of Drug Targeting</i> , 8(1), Database Medline on STN International, Accession No. 2000222278, 2 pages, 2000. |
| | C21 | Bertolini <i>et al.</i> , "Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma," <i>Br. J. Haematol.</i> , 106:5045, 1999. |
| | C22 | Blair <i>et al.</i> , "Linkage of cytotoxin agents to immunoglobulins," <i>Journal of Immunological Methods</i> , 59:129-143, 1983.. |
| | C23 | Blakenberg <i>et al.</i> , "Apoptosis: the importance of nuclear medicine," <i>Nucl. Med. Comm.</i> , 21:241-250, 2000. |
| | C24 | Blakenberg <i>et al.</i> , "Imaging of apoptosis (programmed cell death) with ^{99m} Tc annexin V.," <i>J. Nucl. Med.</i> , 40:184-191, 1999. |
| | C25 | Blakenberg <i>et al.</i> , "In vivo detection and imaging of phosphatidylserine expression during programmed cell death," <i>Proc. Natl. Acad. Sci., USA</i> , 95:6349-6354, 1998. |
| | C26 | Block, "Poly(g-benzyl-L-glutamate) and other glutamic acid containing polymers," Gordon and Breach Science Publishers, New York, 11-31, 1983. |
| | C27 | Blondeau <i>et al.</i> , "Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid," <i>Can J. Chem.</i> , 45:49-52, 1967. |
| | C28 | Bohdiewicz <i>et al.</i> , "Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging," <i>J. Nuclear Medicine Technology</i> , 26(3):155-163, 1998. |
| | C29 | Bormans <i>et al.</i> , "Synthesis and biological characteristics of the four stereoisomers of ^{99m} Tc-N, N'-bis-(mercaptoacetyl)2,3-diaminopropanoate," <i>Int. J. Rad. Appl. Instrum. B.</i> , 17(5):499-506, 1990. |
| | C30 | Brechbiel <i>et al.</i> , "Synthesis of 1 (P-isothiocyanatobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor-imaging studies," <i>Inorg. Chem.</i> , 25:2772-2781, 1986. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C31 | Brogi <i>et al.</i> , "Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression," <i>J. Clin. Invest.</i> , 97(2):469-476, 1996. |
| | C32 | Brokx <i>et al.</i> , "Designing peptide-based scaffolds as drug delivery vehicles," <i>Science</i> , 78(1-3):115-123, 2002. |
| | C33 | Budihardjo <i>et al.</i> , "Biochemical pathways of caspase activation during apoptosis," <i>Annu. Rev. Cell Dev. Biol.</i> , 15:269-290, 1999. |
| | C34 | Burgen, "Targets of drug action," <i>Ann. Rev. Pharmacol. Toxicol.</i> , 40:1-16, 2000. |
| | C35 | Burian <i>et al.</i> , <i>Acta Otolaryngol.</i> , 119:289-292, 1999. |
| | C36 | Bush <i>et al.</i> , "Definitive evidence for hypoxic cells influencing cure in cancer therapy," <i>Br J Cancer</i> , (Suppl. III) 37:302-306, 1978. |
| | C37 | Campbell <i>et al.</i> , "Folate-binding protein is a marker for ovarian cancer," <i>Cancer Res</i> , 51:5329-5338, 1991. |
| | C38 | Cao, "Therapeutic potentials of angiostatin in the treatment of cancer," <i>Haematologica</i> , 84:643-650, 1999. |
| | C39 | Chapman <i>et al.</i> , "Therapeutic antibody fragments with prolonged in vivo half-lives," <i>Nature Biotech.</i> , 17:780-783, 1999. |
| | C40 | Chen <i>et al.</i> , "Biological and pharmacokinetic evaluation of tc-99m ma2g2-b: a potential renal agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1082, 1994. |
| | C41 | Cherif <i>et al.</i> , "Rapid synthesis of [¹⁸ F]Fluoro-1-(2'-Nitro-1'-Imidazolyl)-2-Propanol ([¹⁸ F]Fluoromisonidazole)," <i>Pharm Res.</i> , 11:466-469, 1994. |
| | C42 | Cleynhens <i>et al.</i> , "Synthesis and biological evaluation in mice of a monoamide derivative of tc-99m-l,l-ec," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 799, 1997. |
| | C43 | Collier <i>et al.</i> , "Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT," <i>Radiology</i> , 185:179-186, 1992. |
| | C44 | Coney <i>et al.</i> , "Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing," <i>Cancer Res</i> , 54:2448-2455, 1994. |
| | C45 | Corlija <i>et al.</i> , "Contribution of radiolytically induced dissociation of 99mtc-d,l-hmpao in aqueous solutions," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 413, 1990. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C46 | Craig <i>et al.</i> , "Renal outcomes for children on year after urinary tract infection," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 175, 1996. |
| | C47 | Culver <i>et al.</i> , "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> , 256:1550-1552, 1992. |
| | C48 | Dagli <i>et al.</i> , "Analysis of the complete dynamic scan data for camera-based determination of renal function," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 354, 1996. |
| | C49 | Davison <i>et al.</i> , "A new class of oxotechnetium(5+) chelate complexes containing a TcON ₂ S ₂ Core," <i>Inorg Chem</i> , 20:1629-1632, 1981. |
| | C50 | de Klerk <i>et al.</i> , "Aspirin versus captopril renography in the diagnosis of renal artery stenosis," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1291, 1996. |
| | C51 | Deguchi <i>et al.</i> , "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker," <i>Bioconjugate Chem.</i> , 10:32-37, 1999. |
| | C52 | DeNardo <i>et al.</i> , "Pharmacokinetics of chimeric L6 conjugated to indium 111- and yttrium-90-DOTA-peptide in tumor-bearing mice," <i>J. Nuclear Medicine</i> , 36:829-836, 1995. |
| | C53 | DeNardo <i>et al.</i> , "Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer," <i>Anticancer Research</i> , 17(3B):1735-1744, 1997. |
| | C54 | Deutsch <i>et al.</i> , "Synthesis of congeners and prodrugs, water-soluble prodrugs of taxol with potent antitumor activity," <i>J. Med. Chem.</i> , 32:788-792, 1989. |
| | C55 | Deveraux and Reed, "IAP family proteins-suppressors of apoptosis," <i>Genes and Development</i> , 13:239-252, 1999. |
| | C56 | Dewanjee <i>et al.</i> , "Labeling antisense oligodeoxynucleotide (on) with tc-99m and hybridization with c-myc oncogene mrna in p388 leukemic cells," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1081, 1994. |
| | C57 | Dezutter <i>et al.</i> , "Preparation and biological evaluation of technetium- ^{99m} -L,L-propylenedicysteine" <i>J. of Labelled Cpd. Radiopharm.</i> , 42:553-565, 1999. |
| | C58 | Dische, "A review of hypoxic-cell radiosensitization," <i>Int J Radiat Oncol Biol Phys</i> , 20:147-152, 1991. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C59 | Divgi <i>et al.</i> , "Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma," <i>J. National Cancer Institute</i> , 83(2):97-104, 1991. |
| | C60 | Drobnik <i>et al.</i> , "Soluble synthetic polymers in biological systems," <i>Adv. Polym. Sci.</i> , 57:1-50, 1984. |
| | C61 | Dunn <i>et al.</i> , "Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics," <i>J. Cell Biol.</i> , 98:2148-2159, 1984. |
| | C62 | Eary <i>et al.</i> , "Radiochemistry of halogenated antibodies," <i>Antibodies in Radiodiagnosis and Therapy</i> , Boca Ratan, Florida, CPC Press, 83-100, 1988. |
| | C63 | Eiseman <i>et al.</i> , "Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice," <i>Cancer Chemother. Pharmacol.</i> , 34:465-471, 1994. |
| | C64 | Eisenhut <i>et al.</i> , "Synthesis and <i>In Vivo</i> Testing of a bromobutyl substituted 1,2-Dithia-5,9-diazacycloundecane: a versatile precursor for new ^{99m} Tc-bis(aminoethanethiol) complexes," <i>Nucl. Med. Biol.</i> , 16:805-811, 1989. |
| | C65 | Ennis <i>et al.</i> , "Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells," <i>Mol. Endocrinology</i> , 3(11):1830-1838, 1989. |
| | C66 | Eshima <i>et al.</i> , "Evaluating the role of protein binding on the renal extraction of tc-99m tubular agents utilizing an isolated perfused rat kidney model," <i>J. Nuclear Med.</i> , 37:47P, Abstract No. 178, 1996. |
| | C67 | Ethier, "Growth factor synthesis and human breast cancer progression," <i>J. Natl. Cancer Inst.</i> , 87(13):964-973, 1995. |
| | C68 | Fan <i>et al.</i> , "Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts," <i>Cancer Research</i> , 53:4637-4642, 1993. |
| | C69 | Fan <i>et al.</i> , "Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies," <i>Cancer Research</i> , 53:4322-4328, 1993. |
| | C70 | Fanciulli <i>et al.</i> , "Glycolysis and growth rate in normal and in hexokinase-transfected NIH-3T3 cells," <i>Oncology Res.</i> , 6:405-409, 1994. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C71 | Fang <i>et al.</i> , "Involvement of p21 Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells," <i>Anticancer Research</i> , 20(1A):103-112, 2000. |
| | C72 | Fidler <i>et al.</i> , "The biology of cancer invasion and metastasis," <i>Adv. Cancer Res.</i> , 28:149-250, 1987. |
| | C73 | Foa <i>et al.</i> , "Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity," <i>J. Clin. Lab. Res.</i> , 24:6-14, 1994. |
| | C74 | Frankel <i>et al.</i> , "Targeted toxins," <i>Clin. Cancer Res.</i> , 6:326-334, 2000. |
| | C75 | Franklin <i>et al.</i> , "New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma," <i>Int J Cancer-Supplement</i> , 8:89-95, 1994. |
| | C76 | Frisch and Screaton, "Anoikis mechanisms," <i>Curr. Opin. Cell Biol.</i> , 13:555-562, 2001. |
| | C77 | Fuertges <i>et al.</i> , "The clinical efficacy of poly(ethylene glycol)-modified porteins," <i>J. Controlled Release</i> , 11:139-148, 1990. |
| | C78 | Fuller <i>et al.</i> , "A procedure for the facile synthesis of amino-acid N-carboxyanhydride," <i>Biopolymers</i> , 15:1869, 1976. |
| | C79 | Gabizon, "Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes," <i>Cancer Research</i> , 52:891-896, 1992. |
| | C80 | Gambhir <i>et al.</i> , "A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography," <i>Proc. Natl. Acad. Sci., USA</i> , 97(6):2785-2790, 2000. |
| | C81 | Gambhir <i>et al.</i> , "Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography," <i>Proc. Natl. Acad. Sci., USA</i> , 96:2333-2338, 1999. |
| | C82 | Gambhir <i>et al.</i> , "Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir," <i>J. Nucl. Med.</i> , 39:2003-2011, 1998. |
| | C83 | Garayoa <i>et al.</i> , "Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis," <i>Molecular Endocrinology</i> , 14:848-862, 2000. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C84 | Garipey <i>et al.</i> , "Vectorial delivery of macromolecules into cells using peptide-based vehicles," <i>Trends in Biotechnology</i> , 19(1):21-28, 2001. |
| | C85 | Girard, "Mechanisms by which carbohydrates regulate expression genes for glycolytic and lipogenic enzymes," <i>Ann. Rev. Nutr.</i> , 17:325-352, 1997. |
| | C86 | Giraud <i>et al.</i> , "Application to a cartilage targeting strategy: Synthesis and in vivo biodistribution of ¹⁴ C-labelled quaternary ammonium-glucosamine conjugates," <i>Bioconjug. Chem.</i> , 11:212-218, 2000. |
| | C87 | Goh <i>et al.</i> , "Growth hormone promotion of tubulin polymerization stabilizes the microtubule network and protects against colchicine-induced apoptosis," <i>Endocrinology</i> , 139:4364-4372, 1998. |
| | C88 | Goldenberg <i>et al.</i> , "Imaging of human tumor xenografts with and indim-111-labeled anti-epidermal growth factor receptor monoclonal antibody," <i>J. National Cancer Institute</i> , 81:1616-1625, 1989. |
| | C89 | Goldenberg, "Monoclonal antibodies in cancer detection and therapy," <i>Am. J. Med.</i> , 94:297-312, 1993. |
| | C90 | Goldsmith <i>et al.</i> , "Somatostatin receptor imaging in lymphoma," <i>Sem Nucl Med</i> , 25:262-271, 1995. |
| | C91 | Goldsmith, "Receptor imaging: Competitive or complementary to antibody imaging," <i>Sem Nucl Med.</i> , 27:85-93, 1997. |
| | C92 | Goldspeil, "Pharmaceutical issues: preparation, administration, stability, and compatibility with other medications," <i>Ann. Pharmacother.</i> , 28:S23-S26, 1994. |
| | C93 | Gonda, "Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 6(4):273-313, 1990. |
| | C94 | Green and Evan, "A matter of life and death," <i>Cancer Cell</i> , 1:19-30, 2002. |
| | C95 | Greenfield <i>et al.</i> , "In vitro evaluation of immunoconjugates prepared by linking mitomycin C to monoclonal antibodies via polyglutamic acid carriers," <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 2(3):201-216, 1989. |
| | C96 | Greenwald <i>et al.</i> , "Drug delivery systems: water soluble tazol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness," <i>J. Med. Chem.</i> , 39:424-431, 1996. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C97 | Guozheng and Boli, "A new potential renal imaging agent 99mtcn-ec," <i>J. Labelled compounds and Radiopharmaceuticals</i> , XXXVII:797-798, 1995. |
| | C98 | Hadley et al, "Magnetic resonance imaging in acute head injury," <i>Clin. Rad.</i> , 39:131-139, 1988. |
| | C99 | Halpern <i>et al.</i> , "Stability, characterization, and kinetics of In-labeled monoclonal antitumor antibodies in normal animals and nude mouse human tumor models," <i>Cancer Research</i> , 43:5347-5355, 1983. |
| | C100 | Harada <i>et al.</i> , "Insulin-induced egr-1 expression in chinese hamster ovary cells in insulin receptor an dinsulin receptor substrate-1 phosphorylation-independent," <i>J. Biol Chem.</i> , 270:26632-26638, 1995. |
| | C101 | Hay <i>et al.</i> , "Hypoxia-selective antitumor agents. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers," <i>J Med. Chem.</i> , 37:381-391, 1994. |
| | C102 | Hermann and Patel, "Adaptive recognition by nucleic acid aptamers," <i>Science</i> , 287:820-825, 2000. |
| | C103 | Hermanson, "Amine detection reagents," <i>Bioconjugate Techniques</i> , San Diego, Academic Press, 112-114, 1996. |
| | C104 | Hermanson, "Ellman's assay for the determination of sulfhydryls," <i>Bioconjugate Techniques</i> , Sand Diego, Academic Press, 88-90, 1996. |
| | C105 | Hibi <i>et al.</i> , "PGP9.5 as a candidate tumor marker for non-small-cell lung gancer," <i>American Journal of Pathology</i> , 155(3):711-715, 1999. |
| | C106 | Hnatowich <i>et al.</i> , "Radioactive labeling of antibody: a simple and efficient method," <i>Science</i> , 220:613-615, 1983. |
| | C107 | Hoes <i>et al.</i> , "Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin," <i>J. Controlled Release</i> , 2:205-213, 1985. |
| | C108 | Holm <i>et al.</i> , "Folate receptor of human mammary adenocarcinoma," <i>APMIS</i> , 102:413-419, 1994. |
| | C109 | Holmes <i>et al.</i> , "Current status oc clinical trials with paclitaxel and docetael, taxane anticancer agents: basic science and current status," <i>American Chemical Society</i> , Washington, DC, 31-57, 1995. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C110 | Hsueh and Dolnick, "Altered folate-binding protein mRNA stability in KB cells grown in folate-deficient medium," <i>Biochem Pharmacol</i> , 45:2537-2545, 1993. |
| | C111 | Hudecz <i>et al.</i> , "Influence of carrier on biodistribution and in vitro cytotoxicity of methotexate-branched polypeptide conjugates," <i>Bioconjugate Chemistry</i> , American Chemical Society, 4(1):25-33, 1993. |
| | C112 | Ilgan <i>et al.</i> , " ^{99m} Tc-ethylenedicycysteine-folate: a new tumor imaging agent, synthesis, labeling and evaluation in animals," <i>Cancer Biotherapy & Radiopharmaceuticals</i> , 13:427-435, 1998. |
| | C113 | Inoue <i>et al.</i> , "Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma," <i>Clinical Cancer Res.</i> , 6:4874, 4884, 2000. |
| | C114 | Inoue <i>et al.</i> , "The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy," <i>Clin. Cancer Res.</i> , 6:4866-4873, 2000. |
| | C115 | Ionov <i>et al.</i> , "Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution," <i>Proc. Natl. Acad. Sci., USA</i> , 97(20):10872-10877, 2000. |
| | C116 | Irie <i>et al.</i> , "Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2," <i>Proc. Natl. Acad. Sci., USA</i> , 83:8694-8698, 1986. |
| | C117 | Itoh <i>et al.</i> , "Graphic (patlak) method in tc-99m-mag3 renal scintigraphy: noninvasive calculation of extraction fraction (ef) and renal plasma flow (RPF)," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1300, 1996. |
| | C118 | Iyer <i>et al.</i> , "8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET," <i>J. Nucl. Med.</i> , 42(1):96-105, 2001. |
| | C119 | Jamar <i>et al.</i> , "Clearance of the new tubular agent Tc-99m L,L-ethylenedicycysteine: Estimation by a simplified method," <i>J Nucl Med</i> , 34:129P, 1993. |
| | C120 | Jeppesen <i>et al.</i> , "Impact of polymer tether length on multiple ligand-receptor bond formation," <i>Science</i> , 293:465-468, 2001. |
| | C121 | John <i>et al.</i> , "Tc-99m labeled ethylenediamines: quest for sigma receptor chelates," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 798, 1997. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C122 | Jones and Mayer, "Glucose metabolism in the rat small intestine: the effect of glucose analogues on hexokinase activity," <i>Biochem. J.</i> , 132:125-128, 1973. |
| | C123 | Jurisson <i>et al.</i> , "Potential technetium small molecule radiopharmaceuticals," <i>Chem. Rev.</i> , 99:2205-2218, 1999. |
| | C124 | Kabasakal <i>et al.</i> , "Clinical comparison of technetium- ^{99m} -ec, technetium- ^{99m} -MAG3 and iodine-131-OIH in renal disorders," <i>J. Nucl. Med.</i> , 36(2):224-228, 1995. |
| | C125 | Kabasakal <i>et al.</i> , "Evaluation of technetium-99m-ethylenedicycysteine in renal disorders and determination of extraction ratio," <i>J. Nucl. Med.</i> , 36(8):1398-1403, 1995. |
| | C126 | Kabasakal <i>et al.</i> , "Prospective validation of single plasma sample ^{99m} Tc-ethylenedicycysteine clearance in adults," <i>J. Nucl. Med.</i> , 40:429-431, 1999. |
| | C127 | Kabasakal <i>et al.</i> , "Simplified technetium- ^{99m} -EC clearance in adults from a single plasma sample," <i>J. Nuclear Med.</i> , 38:1784-1786, 1997. |
| | C128 | Kabasakal. "Technetium-99m ethylene dicycysteine: a new renal tubular function agent," <i>Eur. J Nucl. Med.</i> 27:351-357, 2000. |
| | C129 | Kanazawa <i>et al.</i> , "19F NMR of 2-deoxy-2-fluoro-D-glucos for tumor diagnosis in mice. An NDP-bound hexose analog as a new NMR target for imaging," <i>NMR in Biomed.</i> , 10:35-41, 1997. |
| | C130 | Kanvinde <i>et al.</i> , "Technetium-99m-γ-pyrones: a new class of tc-99m cationic complexes," <i>J. Nuclear Medicine</i> , 31:908, Abstract, 1990. |
| | C131 | Kao <i>et al.</i> , "Detection of esophageal carcinoma using Tc-99m MIBI SPECT imaging," <i>Clin. Nucl. Med.</i> , 19(12):1069-1074, 1994. |
| | C132 | Kao <i>et al.</i> , "Relationship of alveolar permeability and lung inflammation in patients with active diffuse infiltrative lung disease detected by 99Tcm-DTPA radioaerosol inhalation lung scintigraphy and quantitative 67Ga lung scans," <i>Nucl. Med. Commun.</i> , 15(10):850-854, 1994. |
| | C133 | Kao <i>et al.</i> , "Role of radioisotope penile plethysmography in the evaluation of penile hemodynamic of impotent patients," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1304, 1996. |
| | C134 | Kao <i>et al.</i> , "Tc-99m MIBI uptake in breast carcinoma and axillary lymph node metastases," <i>Clin. Nuc. Med.</i> , 19(10):898-900, 1994. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C135 | Kato and Sugiyama, "Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 14(3):287-331, 1997. |
| | C136 | Kato <i>et al.</i> , "A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid-a-fetoprotein antibody-daunomycin conjugate," <i>J. Med. Chem.</i> , 27:1602-1607, 1984. |
| | C137 | Kengen, "Good results of tc-99m-mag3 clearance measurements with a dual headed gamma camera without plasma sampler," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 353, 1996. |
| | C138 | Kikukawa <i>et al.</i> , "Early and delayed Tc-99m ECD brain SPECT in SLE patients with CNS involvement," <i>Ann Nucl Med.</i> 14:25-32, 2000. |
| | C139 | Kim <i>et al.</i> , "Synthesis, biodistribution and imaging of mammary tumors using 99mTc-ec-polyglutamate; a glutamate receptor peptide," <i>J. Nuclear Medicine</i> , 41:231P Abstract, 2000. |
| | C140 | Kitamura <i>et al.</i> , "Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy," <i>Cancer Research</i> , 51:4310-4315, 1991. |
| | C141 | Klok <i>et al.</i> , "Star-shaped fluorescent polypeptides," <i>Journal of Polymer Science</i> , 39(10):1572-1582, 2001. |
| | C142 | Knight <i>et al.</i> , "Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets," <i>J. Nucl. Med.</i> , 35:282-288, 1994. |
| | C143 | Koh <i>et al.</i> , "Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole," <i>Int J Radiat Oncol Biol Phys</i> , 22:199-212, 1992. |
| | C144 | Kopecek <i>et al.</i> "Targetable polymeric prodrugs," <i>J. Control. Release</i> , 6:315-327, 1987. |
| | C145 | Kopecek <i>et al.</i> , "Targetable water-soluble polymeric anticancer drugs: achievements and unsolved problems," <i>Proc. Intern. Symp. Conol. Rel. Bioact. Mater.</i> , 20:190-191, 1993. |
| | C146 | Kopecek, "The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery," <i>Journal of Controlled Release</i> , 11:279-290, 1990. |
| | C147 | Kranz <i>et al.</i> , "Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis," <i>Proc Natl Acad Sci</i> , 92:9057-9061, 1995. |
| | C148 | Lamberts <i>et al.</i> , "Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog," <i>J. Steroid Biochem Mol Biol</i> , 37:1079-1082, 1990. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C149 | Lamki, "Radioimmunoscinigraphy of cancer: problems, pitfalls, and prospects," <i>Nuclear Medicine Annual 1990</i> , New York, Raven Press Ltd., 113-150, 1990. |
| | C150 | Larson <i>et al.</i> , "Overview of clinical radioimmunodetection of human tumors," <i>Cancer</i> , 73(supp):832-835, 1994. |
| | C151 | Leamon and Low, "Cytotoxicity of momordin-folate conjugates in cultured human cells," <i>J Biol Chem</i> , 267:24966-24971, 1992. |
| | C152 | Leamon and Low, "Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis," <i>Proc Natl Acad Sci</i> , 88:5572-5576, 1991. |
| | C153 | Leamon <i>et al.</i> , "Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells," <i>J Biol Chem</i> , 268:24847-24854, 1993. |
| | C154 | Lee and Low, "Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis," <i>J Biol Chem</i> , 269:3198-3204, 1994. |
| | C155 | Li <i>et al.</i> , "Antitumor activity of poly (L-glutamic acid)-paclitaxel on syngeneic and xenograft tumors," <i>Clinical Cancer Res.</i> , 5:891-897, 1999. |
| | C156 | Li <i>et al.</i> , "Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate," <i>Cancer Res.</i> , 58:2404-2409, 1998. |
| | C157 | Li <i>et al.</i> , "Poly(L-glutamic acid)-anticancer drug conjugates," <i>Advanced Drug Delivery Rev.</i> , 54:695-713, 2002. |
| | C158 | Li <i>et al.</i> , "Synthesis and evaluation of water-soluble polyethylene glycol paclitaxel conjugate as a paclitaxel prodrug," <i>Anticancer Drugs</i> , 7(5):642-648, 1996. |
| | C159 | Li <i>et al.</i> , "Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates," <i>Bioconjugate Chem.</i> , 4:275-283, 1993. |
| | C160 | Liang <i>et al.</i> , "The use of diaminodithiol for labeling small molecules with technetium-99m," <i>Nucl. Med. Biol.</i> , 14:63-67, 1987. |
| | C161 | Lin <i>et al.</i> , "The role of Tc-99m MDP and Ga-67 imaging in the clinical evaluation of malignant fibrous histiocytoma," <i>Clin. Nucl. Med.</i> , 19(11):996-1000, 1994. |
| | C162 | Liu <i>et al.</i> , "99mTc-labeled small peptides as diagnostic radiopharmaceuticals," <i>Chem. Rev.</i> , 99:2235-2268, 1999. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C163 | Liu <i>et al.</i> , "Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77," <i>Nature</i> , 367(6460):281-284, 1994.1994. |
| | C164 | Liu <i>et al.</i> , "Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals," <i>Bioconjugate Chemistry</i> , 12:7-34, 2001. |
| | C165 | Liu <i>et al.</i> , "Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole," <i>Eur. J. Nucl. Med.</i> , 23(10):1384-1387, 1996. |
| | C166 | Liu <i>et al.</i> , "Induction of apoptosis and activation of the capase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the C-jun N-terminal kinase activity," <i>British Journal of Cancer</i> , 82(12):1991-1999, 2000. |
| | C167 | Lu <i>et al.</i> , "Polymerizable fab' antibody fragments for targeting of anticancer drugs," <i>Nat. Biotech.</i> , 17:1101-1104, 1999. |
| | C168 | Lu, "Antimitotic agents," In: Foye, WO. Ed., "Cancer chemotherapeutic agents," Washington, DC: American Chemical Society, 345-368, 1995. |
| | C169 | Macapinlac <i>et al.</i> , "Callium-67-citrate imaging in nuclear oncology," <i>Nucl. Med. Biol.</i> , 21(5):731-738, 1994. |
| | C170 | Maeda <i>et al.</i> , "Tumortropic and lymphotropic principles of macromolecular drugs," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 6(3):193-210, 1989. |
| | C171 | Maeda, "SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy," <i>Adv. Drug Delivery Rev.</i> , 6(2):181-202, 1991. |
| | C172 | Makin and Hickman, "Apoptosis and cancer chemotherapy," <i>Cell Tissue Res.</i> , 301:143-152, 2000. |
| | C173 | Mangera and Verbruggen, "Synthesis and evaluation of .beta .-homocysteine derivatives of 99mTc-L, L-EC and 99mTc-L, L-ECD," <i>J. Labelled Comp.Radiopharm.</i> , 42:683-699, 1999. |
| | C174 | Mann <i>et al.</i> , "Molecular amplifiers: synthesis and functionalization of a poly(aminopropyl dextran bearing a uniquely reactive terminus for univalent attachment to biomolecules," <i>Bioconjugate Chemistry</i> , 3:154-159, 1992. |
| | C175 | Marti and Risau, "Systematic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors," <i>Proc. Natl. Acad. Sci., USA</i> , 95:15809-15814, 1998. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C176 | Martin <i>et al.</i> , "Enhanced binding of the hypoxic cell marker [³ H]fluoromisonidazole in ischemic myocardium," <i>J Nucl Med</i> , 30:194-201, 1989. |
| | C177 | Martin <i>et al.</i> , "Noninvasive detection of hypoxic myocardium using fluorine-18 fluoromisonidazole and positron emission tomography," <i>J. Nucl. Med.</i> , 33(12):2202-2208, 1992. |
| | C178 | Mason <i>et al.</i> , "99mtc-desferoxamine: production, stability and solute clearance measurements after aerosolization," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 865, 1990. |
| | C179 | Masui <i>et al.</i> , "Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies," <i>Cancer Research</i> , 44:1002-1007, 1984. |
| | C180 | Mather <i>et al.</i> , "Tumour cell uptake of technetium dithiocarbamate complexes," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 797, 1997. |
| | C181 | Mathew <i>et al.</i> , "Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity," <i>J. Med. Chem.</i> , 35:145-151, 1992. |
| | C182 | Mathias <i>et al.</i> , "Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of Gallium- 67- deferoxamine- folate," <i>J Nucl Med</i> , 37:1003-1008, 1996. |
| | C183 | Mathias <i>et al.</i> , "Indium-111-DTPA-folate as a radiopharmaceutical for targeting tumor-associated folate binding protein," <i>J Nucl Med</i> , (Supplement) 38:133P, 1997. |
| | C184 | Mathias <i>et al.</i> , "Synthesis of Tc-99m-DTPA-folate and preliminary evaluation as a folate-receptor-targeted radiopharmaceutical," <i>J Nucl Med</i> , (Supplement); 38:87P, 1997. |
| | C185 | Meares <i>et al.</i> , "Macrocyclic chelates of radiometals for diagnosis and therapy," <i>British J. Cancer</i> , 62:21-26, 1990. |
| | C186 | Mease <i>et al.</i> , "Comparison of renal agents for detecting unilateral acute ischemic/reperfusion renal injury in rats," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1033, 1995. |
| | C187 | Mendelsohn <i>et al.</i> , "Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking autocrine pathway," <i>Trans. Assoc. Am. Phys.</i> , 100:173-178, 1987. |
| | C188 | Mendelsohn, "Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy," <i>Clinical Cancer Research</i> , 3:2703-2707, 1997. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C189 | Meredith <i>et al.</i> , "Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49," <i>J. Nucl. Med.</i> , 35(6):1017-1022, 1994. |
| | C190 | Michiels <i>et al.</i> , "Simultaneous estimation of effective renal plasma flow and glomerular filtration rate using tc-99m-ec," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 355, 1996. |
| | C191 | Miltross <i>et al.</i> , "Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel," <i>J. National Cancer Institute</i> , 88(18):1308-1314, 1996. |
| | C192 | Mitchell <i>et al.</i> , "Active-specific immunotherapy for melanoma," <i>J. Clin. Oncol.</i> , 8(5):856-869, 1990. |
| | C193 | Mochizuki <i>et al.</i> , "Synthesis of poly-L-glutamates containing 5-substituted uracil moieties," <i>Nucleic Acids Symp. Ser.</i> , 16:121-124, 1985. |
| | C194 | Modjahedi <i>et al.</i> , "The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review)," <i>Int. J. Oncology</i> , 4(2):277-296, 1994. |
| | C195 | Moller <i>et al.</i> , "Biologic activities of naturally occurring human insulin receptor mutations," <i>J. Biol. Chem.</i> , 266:10995-11001, 1991. |
| | C196 | Moran, "Technetium- ^{99m} -EC and other potential new agents in renal nuclear medicine," <i>Seminars in Nucl. Med.</i> , 29: 91-101, 1999. |
| | C197 | Morton <i>et al.</i> , "Comparison of 2-point postural drainage with diuresis renography in the assessment hydronephrosis," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 174, 1996. |
| | C198 | Morton <i>et al.</i> , "Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine," <i>Ann. Surg.</i> , 216(4):463-482, 1992. |
| | C199 | Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay," <i>J. Immunol. Methods</i> , 65:55-63, 1983. |
| | C200 | Mrhac <i>et al.</i> , "Abnormal first-pass flow through the azygos vein from valsalva maneuver," <i>Clinical Nucl. Med.</i> , 21:331-332, 1996. |
| | C201 | Namavari <i>et al.</i> , "Synthesis of 8-[¹⁸ F]Fluoroguanin derivatives: in vivo probes for imaging gene expression with positron emission tomography," <i>Nucl. Med. Biol.</i> , 27:157-162, 2000. |
| | C202 | Nicolaou <i>et al.</i> , "Design, synthesis, and biological activity of protaxols," <i>Nature</i> , 364:464-466, 1993. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C203 | Nosco <i>et al.</i> , "Development of a kit formulation for 99mTcMAG3 of very high purity and very high stability," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 863, 1990. |
| | C204 | Offield <i>et al.</i> , "PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum," <i>Development</i> , 122:983-995, 1996. |
| | C205 | Oldham <i>et al.</i> , "Comparison of action of paclitaxel and poly (L-glutamic acid)-paclitaxel conjugate in human breast cancer cells," <i>Int. J. Oncol.</i> , 16(1):125-132, 2000. |
| | C206 | Olexa <i>et al.</i> , "Radiolabeling of fibrinogen using the lodogen technique," <i>Throm. Haemostas.</i> , 46(3):593-596, 1982. |
| | C207 | Omelyanenko <i>et al.</i> , "HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates: influence of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro," <i>J. Drug Targeting</i> , 3:357-373, 1996. |
| | C208 | Omelyanenko <i>et al.</i> , "HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates II. Processing in epithelial ovarian carcinoma cells in vitro," <i>International Journal of Cancer</i> , 75(4):600-608, 1998. |
| | C209 | Orr <i>et al.</i> , "Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers," <i>J Natl Cancer Inst</i> , 87:299-303, 1995. |
| | C210 | Ozanne <i>et al.</i> , "Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas," <i>J. Pathol.</i> , 149:9-14, 1986. |
| | C211 | Ozker <i>et al.</i> , "Technetium- ^{99m} -N,N-ethylenedicysteine-a comparative study of renal scintigraphy with technetium- ^{99m} -MAG3 and iodine-131-OIH in patients with obstructive renal disease," <i>J. Nucl. Med.</i> , 35:840-845, 1994. |
| | C212 | Pedley <i>et al.</i> , "The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody," <i>British J. Cancer</i> , 70:1126-1130, 1994. |
| | C213 | Petrak <i>et al.</i> , "Transport of macromolecules across the capillary walls," <i>Adv. Drug Deliv. Review</i> , 3:191-214, 1989. |
| | C214 | Phillips-Hughes <i>et al.</i> , "Restenosis: pathophysiology and preventive strategies," <i>JVIR</i> , 7:321-333, 1996. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C215 | Pietersz <i>et al.</i> , "Specific in vitro anti-tumor activity of methotrexate-monooclonal antibody conjugates prepared using human serum albumin as an intermediary," <i>Immunol. Cell Biol.</i> , 66:43-49, 1988. |
| | C216 | Pimm <i>et al.</i> , "Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody II: biodistribution studies in mice with human tumor xenografts," <i>Dur. J. Nucl. Med.</i> , 11:300-304, 1985. |
| | C217 | Pimm <i>et al.</i> , "Strategies for labelling branched polypeptides with a poly (L-Lysine) backbone with radioiodines 123I, 125I, 131I) and radiometals (111In, 51Cr) for biodistribution studies wnad radiopharmaceutical development," <i>Journal of Labelled Compunds and Radiopharmaceuticals</i> , 36(2):157-172, 1995. |
| | C218 | Piper <i>et al.</i> , "A synthetic approach to poly(γ -glutamyl) conjugates of methotrexate," <i>J. Med. Chem.</i> , 26:291-294, 1983. |
| | C219 | Pirmettis <i>et al.</i> , "Synthesis and characterization of the tcd(ec) complex, a renal imaging agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1079, 1994. |
| | C220 | Popovici <i>et al.</i> , "The influence of some antibiotics on hexokinase and pyruvate-kinase activity in the rat liver and kidney," <i>Arch. int. Pharmacodyn.</i> , 193:80-86, 1971. |
| | C221 | Potamianos <i>et al.</i> , "Radioimmunosintigraphy and radioimmunotherapy in cancer: principles and application," <i>Anticancer Research</i> , 20(2A):925-948, 2000. |
| | C222 | Prvulovich <i>et al.</i> , "Clinical evaluation of technetium- ^{99m} -L,L-ethylenedicysteine in patients with chronic renal failure," <i>J. Nucl. Med.</i> , 38:809-814, 1997. |
| | C223 | Putnam <i>et al.</i> , "Polymer conjugates with anticancer activity," <i>Polymer Science</i> , 122:55-123, 1995. |
| | C224 | Quadri <i>et al.</i> , "Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates," <i>Quart. J. Nucl., Med.</i> , 42:250-261, 1998. |
| | C225 | Raffauf <i>et al.</i> , "Colchicine. Derivatives of trimethylcolchicinic acid," <i>J. Am Chem Soc.</i> , 75:5292-5294, 1953. |
| | C226 | Rasey <i>et al.</i> , "Characterization of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiat Res</i> , 122:301-308, 1990. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C227 | Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int. J. Radiat Oncol. Biol Phys</i> , 17:985-991, 1989. |
| | C228 | Ratner and Clarke, "The action of formaldehyde upon cysteine," <i>J. Am Chem. Soc.</i> , 59:200-206, 1937. |
| | C229 | Ravindranath <i>et al.</i> , "Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA," <i>J. Immunol. Methods</i> , 16(197):51-67, 1996. |
| | C230 | Reed, "Apoptosis-targeted therapies for cancer," <i>Cancer Cell</i> , 3:17-22, 2003. |
| | C231 | Reilly <i>et al.</i> , "A comparison of EGF and Mab 528 labeled within for imaging human breast cancer," <i>J. Nucl. Med.</i> , 41:903-911, 2000. |
| | C232 | Remington's Pharmaceutical Sciences, 19 th Ed., Mach Printing Company, 1990, Smith and Rutlage, 1975. |
| | C233 | Rihova <i>et al.</i> , "Antiproliferative effect of a lectin- and anti-thy-1.2 antibody-targeted HPMAC copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse thy-1.2 gene," <i>Bioconjugate Chemistry</i> , 11(5):664-673, 2000. |
| | C234 | Rihova, "Receptor-mediated targeted drug or toxin delivery," <i>Adv. Drug Deliv. Rev.</i> , 29:273-289, 1998. |
| | C235 | Rogers <i>et al.</i> , "Neomycin effects on glucose transport by rat small intestine," <i>Digestion</i> , 1:159-164, 1968. |
| | C236 | Rosenberg <i>et al.</i> , "Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients," <i>Ann. Surg.</i> , 210(4):474-548, 1989. |
| | C237 | Ross <i>et al.</i> , "Differential regulation of folate receptor isoforms in normal and malignant tissue in vivo and in established cell lines," <i>Cancer</i> , 73:2432-2443, 1994. |
| | C238 | Roth <i>et al.</i> , "Gene therapy for cancer: what have the inventors done and where are the inventors going?" <i>J. Natl. Can. Inst.</i> , 89(1):21-39, 1997. |
| | C239 | Rowinsky <i>et al.</i> , "Paclitaxel (taxol)," <i>New England Journal of Medicine</i> , 332:1004-1014, 1995. |
| | C240 | Rowinsky <i>et al.</i> , "Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting," <i>J. Clin. Oncol.</i> , 11(10):2010-2020, 1993. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C241 | Rowland <i>et al.</i> , "Suppression of tumor growth in mice by drug-antibody conjugate using a novel approach to linkage," <i>Nature</i> , 255:487-488, 1975. |
| | C242 | Sabbantini <i>et al.</i> , "Early findings in a phase I study of PG-Paclitaxel (CT2103 in recurrent ovarian or primary peritoneal cancer," <i>Proc. AACR-NCI-EORTC Int. Conference on Molecule Targets and Cancer Therapeutics</i> , Abs, 470:96, 2001. |
| | C243 | Sasaki <i>et al.</i> , "Assessment of antioxidative ability in brain: imaging of glutathione localization with technetium-99m meso-hexamethyl propyleneamine," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1083, 1994. |
| | C244 | Sato <i>et al.</i> , "Simple estimation of fractional renal uptake of tc-99m mag3 using graphical analysis without syringe counting and renal depth correction," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1303, 1996. |
| | C245 | Seabold <i>et al.</i> , "Comparison of ^{99m} Tc-Methoxyisobutyl Isonitrile and ²⁰¹ Tl Scintigraphy for Detection of Residual Thyroid Cancer After ¹³¹ I Ablative Therapy," <i>J. Nucl. Med.</i> , 40(9):1434-1440, 1999. |
| | C246 | Semenza, "Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1," <i>Ann. Rev. Cell Dev. Biol.</i> , 15:551-578, 1999. |
| | C247 | Serruys <i>et al.</i> , "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," <i>New England J. Medicine</i> , 331(8):489-495, 1994. |
| | C248 | Seymour <i>et al.</i> , "Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumor-targeted drug delivery," <i>Select. Cancer Therapeut.</i> , 7(2):59-73, 1991. |
| | C249 | Shankar <i>et al.</i> , "Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus," <i>Metabolism</i> , 47:573-577, 1998. |
| | C250 | Shattuck <i>et al.</i> , "Validation of the two sample technique for measuring gfr in renal transplant patients," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1036, 1995. |
| | C251 | Shih <i>et al.</i> , "Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier," <i>Cancer Res.</i> , 54:4192-4198, 1991. |
| | C252 | Shimada <i>et al.</i> , "Biodistribution of liposomes containing synthetic galactose-terminated diacylglycerol-poly(ethylen glycol)s," <i>Biochimica et Biophysica Acta</i> , 1326:329-341, 1997. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C253 | Shuke <i>et al.</i> , "Modified renal counting method for estimation of tc-99m mag3 renal clearance," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1301, 1996. |
| | C254 | Skrzypczak-Jankun <i>et al.</i> , "Structure of the hirugen and hirulog 1 complexes of α -thrombin," <i>J. Mol. Biol.</i> , 221:1379-1393, 1991. |
| | C255 | Smalley <i>et al.</i> , "Localization of fluorescent compounds in the firefly light organ," <i>J. Histochem. Cytochem.</i> , 28(4):323-329, 1980. |
| | C256 | Smith <i>et al.</i> , "Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma," <i>J. Clin. Oncol.</i> , 18(10):2046-2052, 2000. |
| | C257 | Stoffel <i>et al.</i> , "Evaluation of technetium-99m-L ₁ -ec in renal transplant recipients: a comparative study with technetium- ^{99m} -MAG3 and iodine-125-OIH," <i>J. Nucl. Med.</i> , 35:1951-1958, 1994. |
| | C258 | Stuttle <i>et al.</i> , "Imaging of bone infection with labelled white blood cells: role of contemporaneous bone marrow imaging," <i>Eur. J. Nucl. Med.</i> , p17:148-151, 1990. |
| | C259 | Subramanian <i>et al.</i> , "Transchelation reactions in labeling ecd with tc-99m," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 867, 1990. |
| | C260 | Sudimack <i>et al.</i> , "Targeted delivery via folate receptor," <i>Adv. Drug Deliv. Rev.</i> , 41:147-162, 2000. |
| | C261 | Sun <i>et al.</i> , "Idium(III) and Gallium(III) Complexes of Bis(aminoethanethiol) Ligands with Different Denticities: Stabilities, Molecular Modeling, and in Vivo Behavior," <i>Journal of Medicinal Chemistry</i> , 39(2):458(1996). |
| | C262 | Surma <i>et al.</i> , "Usefulness of Tc-99m-N,N'-ethylene-1-dicysteine complex for dynamic kidney investigations," <i>Nucl Med Comm</i> , 15:628- 635, 1994. |
| | C263 | Surwit <i>et al.</i> , "Clinical assessment of In-CYT-103 immunoscintigraphy in ovarian cancer," <i>Gynecol. Oncol.</i> , 48:285-292, 1993. |
| | C264 | Suzuki <i>et al.</i> , "A modified graphic method for estimation of glomerular filtration index using dynamic renal images with tc-99m dtpa," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1035, 1995. |
| | C265 | Taggart <i>et al.</i> , <i>Human Mutation</i> , 13(3):210-220, 1999. |
| | C266 | Tait and Smith, "Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding," <i>Arch Biochem Biophys</i> , 288:141-144, 1991. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C267 | Takamizawa <i>et al.</i> , "Differential apoptosis gene expression in pediatric tumors of the kidney," <i>J. Ped. Surg.</i> , 35(2):390-395, 2000. |
| | C268 | Takashina <i>et al.</i> , "Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol," <i>Jpn. J. Cancer Res.</i> , 82:1145-1150, 1991. |
| | C269 | Tam, "Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system," <i>Proc. Natl. Acad. Sci., USA</i> , 85:5409-5413, 1988. |
| | C270 | Taylor <i>et al.</i> , "Comparison of tc-99m0(n,n1-ethylenedicysteine isomers in rats and in normal volunteers," <i>J. Nuclear Med.</i> , 37:46P-47P, Abstract No. 177, 1996. |
| | C271 | Taylor <i>et al.</i> , "Comparison of technetium- ^{99m} -LL-EC isomers in rats and humans," <i>J. Nucl. Med.</i> , 38:821-826, 1997. |
| | C272 | Tjuvajev <i>et al.</i> , "Comparison of radiolabeled nucleoside probes (FIAU, FHGB, and FHPG) for PET imaging of HSV1-tk gene expression," <i>J. Nucl. Med.</i> , 43:1072-1083, 2002. |
| | C273 | Tomalia <i>et al.</i> , "Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology and flexibility from atoms to macroscopic matter," <i>Angew. Chem. Int. Ed. Engl.</i> , 29:138-175, 1990. |
| | C274 | Torchilin <i>et al.</i> , "Chelating polymer modified monoclonal antibodies for radioimmunodiagnostics and radioimmunotherapy," <i>J. Controlled Release</i> , 24:111-118, 1993. |
| | C275 | Tschopp <i>et al.</i> , "Apoptosis: silencing the death receptors," <i>Curr. Biol.</i> , 9:R381-R384, 1999. |
| | C276 | Tsukamoto <i>et al.</i> , "The quantitation of absolute tc-99m-dmsa renal uptake in children from planar posterior-view method," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1299, 1996. |
| | C277 | Tubis <i>et al.</i> , "The preparation of ^{99m} technetium-labelled cystine, methionine and synthetic polypeptide and their distribution in mice," <i>Int. Journ. Appl. Rad. Isotop.</i> , 19:835-840, 1968. |
| | C278 | Tuli <i>et al.</i> , "Comparison of a simplified quantitation of tc-99m mag-3 renogram to core needle biopsy in the diagnosis of renal transplant rejection," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1290, 1996. |
| | C279 | Ugar <i>et al.</i> , "The diagnosis of renovascular hypertension with technetium-99m-ethylenedicysteine captopril scintigraphy," <i>Investigative Radiology</i> , 31:497-501, 1996. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C280 | Ugur <i>et al.</i> , "Renovascular hypertension due to takayasu's arteritis demonstrated by Tc- ^{99m} ethylenedicycysteine captopril scintigraphy," <i>Clinical Nuclear Medicine</i> , 21:714-716, 1996. |
| | C281 | Ugur <i>et al.</i> , "Technetium- ^{99m} -ethylenedicycysteine in the diagnosis and follow-up of renovascular hypertension," <i>Investigative Radiology</i> , 31:378-381, 1996. |
| | C282 | Ugur <i>et al.</i> , "Technetium- ^{99m} -ethylenedicycysteine: an alternative agent to detect renovascular hypertension," <i>J. of Nuclear Med.</i> , 38:1662-1664, 1997. |
| | C283 | Ugur <i>et al.</i> , "The diagnosis of renovascular hypertension with tc-99m ethylenedicycysteine captopril scintigraphy," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1302, 1996. |
| | C284 | Ugurel <i>et al.</i> , "Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival," <i>J. Clin. Oncol.</i> , 19(2):577-583, 2001. |
| | C285 | Valk <i>et al.</i> , "Hypoxia in human gliomas: Demonstration by PET with [¹⁸ F]fluoromisonidazole," <i>J Nucl Med</i> , 33:2133-2137, 1992. |
| | C286 | Van Heeswijk <i>et al.</i> , "The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adiramycin Part 1," <i>J. Controlled Release</i> , 1:301-315, 1985. |
| | C287 | Van Nerom <i>et al.</i> , "Comparative evaluation of Tc-99m L,L-ethylenedicycysteine and Tc-99m MAG3 in volunteers," <i>Eur J Nucl Med</i> , 16:417, 1990. |
| | C288 | Van Nerom <i>et al.</i> , "Comparison of renal excretion ocharacteristics of isomers l,l and d,d of tc-99m ethylenedicycysteine," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 412, 1990. |
| | C289 | Van Nerom <i>et al.</i> , "Optimalization of the labelling of ethylenedicycysteine (ec) with technetium-99m," <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:37-39, 1991. |
| | C290 | Van Nerom <i>et al.</i> , "First experience in healthy volunteers with Tc-99m-L,L-ethylenedicycysteine, a new renal imaging agent," <i>Eur J Nucl Med</i> , 20:738-746, 1993. |
| | C291 | Van Schepdael <i>et al.</i> , "Capillary electrophoretic analysis of ethylene dicysteine, a precursor of the radiopharmaceutical ^{99m} Tc ethylene dicysteine," <i>J. Chromatography B</i> , 697:251-254, 1997. |
| | C292 | Vega <i>et al.</i> , "Targeting adriamycin to EGF receptors by site-specific conjugation of monoclonal antibody to poly(L-glutamic acid)," Division of Deagnostic Imaging and Departmetn of Experimental Therapeutics, U.T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C293 | Verbruggen <i>et al.</i> , "Evaluation of Tc-99m-L,L-ethylenedicysteine as a potential alternative to Tc-99m MAG3," <i>Eur J Nucl Med</i> , 16:429, 1990. |
| | C294 | Verbruggen <i>et al.</i> , "Is syn or anti orientation of the oxotechnetium and carboxyl group in tc-99m renal function agents affecting the renal excretion rate?" <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:86-88, 1991. |
| | C295 | Verbruggen <i>et al.</i> , "Tc-99m l,l-ethylenedicysteine, a potential alternative to tc-99m mag3," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 864, 1990. |
| | C296 | Verbruggen <i>et al.</i> , "Tc-99m-L,L-ethylenedicysteine: A renal imaging agent. I. Labelling and evaluation in animals," <i>J Nucl Med</i> , 33:551-557, 1992. |
| | C297 | Villevalois-Cam <i>et al.</i> , "Insulin-induced redistribution of the insulin-like growth factor II/mannose 6-phosphate receptor in intact rat liver," <i>J. Cell. Biochem.</i> , 77:310-322, 2000. |
| | C298 | Vyas <i>et al.</i> , "Phosphatase-activated prodrugs of paclitaxel," <i>Taxane Anticancer Agents: Basic Science and Current Status</i> , <i>American Chemical Society</i> , Washington, DC, 124-137, 1995. |
| | C299 | Wahl <i>et al.</i> , "Loss of normal p53 function confers sensation to taxol by increasing g2/m arrest and apoptosis," <i>Nat. Med.</i> , 2(1):72-79, 1996. |
| | C300 | Wahl, "Monoclonal antibodies in nuclear medicine," <i>Nuclear Medicine Annual 1992</i> , New York, Raven Press Ltd., 91-103, 1992. |
| | C301 | Walsh <i>et al.</i> , "Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction," <i>J. Nucl. Med.</i> , 30:1798-1808, 1989. |
| | C302 | Wang <i>et al.</i> , "Design and synthesis of [¹¹¹ In]DTPA-folate for use as a tumor-targeted radiopharmaceutical," <i>Bioconjugate Chem</i> , 8:673-679, 1997. |
| | C303 | Wang <i>et al.</i> , "Synthesis, purification, and tumor cell uptake of Ga-67 deferoxamine-folate, a potential radiopharmaceutical for tumor imaging," <i>Bioconjugate Chem</i> , 7:56- 62, 1996. |
| | C304 | Washburn <i>et al.</i> , "Reliable kit preparation of tc99m pentavalent dimercaptosuccinic acid [tc-99m (v) dmsa]," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1080, 1994. |
| | C305 | Weir <i>et al.</i> , "Prognostic value of single-photon emission tomography in acute ischaemic stroke," <i>Eur. Journ. Nuc. Med.</i> , 24:21-26, 1989. |
| | C306 | Weiss <i>et al.</i> , "Hypersensitivity reaction from taxol," <i>J. Clin. Oncol.</i> , 8(7):1263-1268, 1990. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C307 | Weitman <i>et al.</i> , "Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis," <i>Cancer Res</i> , 52:6708-6711, 1992b. |
| | C308 | Weitman <i>et al.</i> , "The folate receptor in central nervous system malignancies of childhood," <i>J Neuro-Oncology</i> , 21:107-112, 1994. |
| | C309 | Weitman <i>et al.</i> , "Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues," <i>Cancer Research</i> , 52:3396-3401, 1992. |
| | C310 | Wells <i>et al.</i> , "Glycosylation of nucleocytoplasmic proteins: signal transduction and)-glcNAc," <i>Science</i> , 291:2376-2378, 2001. |
| | C311 | Wen <i>et al.</i> , "Conjugation with 111In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225," <i>J. Nuclear Medicine</i> , 42(10):1530-1537, 2001. |
| | C312 | Wen <i>et al.</i> , "Improved radiolabeling of PEFylated protein: PEGylated annexin V for noninvasive imaging of tumor apoptosis," <i>Bioconjugate Chemistry</i> , 2002. |
| | C313 | Wen <i>et al.</i> , "Poly(ethylene glucol) conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains," <i>Bioconjugate Chem.</i> , 12:545-553, 2001. |
| | C314 | Westerhof <i>et al.</i> , "Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: Role of carrier- and receptor- mediated transport systems," <i>Cancer Res</i> , 51:5507-5513, 1991. |
| | C315 | Wu <i>et al.</i> , "Apoptosis induced by and anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin," <i>J. Clin. Invest.</i> , 95:1897-1905, 1995. |
| | C316 | Yaghoubi <i>et al.</i> , "Human pharmacokinetic and dosimetry studies of {18F}FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression," <i>J. Nucl. Med.</i> , 42:1225-1234, 2001. |
| | C317 | Yamori <i>et al.</i> , "Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel," <i>Cancer Res.</i> , 59:4042-4049, 1999. |
| | C318 | Yang <i>et al.</i> , "Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia," <i>Radiology</i> , 194:795-800, 1995. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C319 | Yang <i>et al.</i> , "99mtc-ec-deoxyglucose: synthesis, cellular uptake, biodistribution and scintigraphic imaging," <i>J. Labelled Cpd. Radiopharm.</i> , 44:S513-S514, Abstract, 2001. |
| | C320 | Yang <i>et al.</i> , "Imaging tumor folate receptors using 99mtc-ethylenedicysteine-folate," <i>Proceedings of the American Association for Cancer Research</i> , 40:259, Abstract #1720, 1999. |
| | C321 | Yang <i>et al.</i> , "Imaging tumor folate receptors using radiolabeled folate and methotrexate," <i>J. Labelled Cpd. Radiopharm.</i> , 42:S696-S697, 1999. |
| | C322 | Yang <i>et al.</i> , "Molecular imaging using 99m-tc-ec-nitroimidazole, and 99mtc-ec-annexin v in tumor-bearing rodents," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 41:766, Abstract, 2000. |
| | C323 | Yang <i>et al.</i> , "Noninvasive assesment of tumor hypoxia with 99mTc labeled metronidazole," <i>Pharm. Research</i> , 16:743-750, 1999. |
| | C324 | Yasui <i>et al.</i> , "Expression of epidermal growth factor receptor in human gastric and colonic carcinomas," <i>Cancer Res.</i> , 48:137-141, 1995. |
| | C325 | Ye <i>et al.</i> , "TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction," <i>J. Biol. Chem.</i> , 274(42):30202-30208, 1999. |
| | C326 | Yeh <i>et al.</i> , "Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma," <i>Eur. J. Nucl. Med.</i> , 23(10):1378-1383, 1996. |
| | C327 | Yen <i>et al.</i> , "A comparative study of evaluating renal scars by 99mTc-DSMA planar and SPECT renal scans, intravenous urography, and ultrasonography," <i>Ann. Nucl. Med.</i> , 8(2):147-152, 1994. |
| | C328 | Yen <i>et al.</i> , "Technetium-99m-DMSA renal SPECT in diagnosing and monitoring pediatric acute pyelonephritis," <i>J. Nucl. Med.</i> , 37(8):1349-1353, 1996. |
| | C329 | Yen <i>et al.</i> , "The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans," <i>Eur. J. Nucl. Med.</i> , 21(9):980-983, 1994. |
| | C330 | Yokoyama <i>et al.</i> , "Polymer micelles as novel drug carrier: adriamycin-conjugated poly(ethylen glycol)-poly(aspartic acid) block copolymer," <i>J. Controlled Release</i> , 11:269-278, 1990. |
| | C331 | Yoshino <i>et al.</i> , "Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats," <i>Metabolism</i> . 48:1418-23, 1999. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|---|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSC:841US | Serial No. 10/732,919 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant David J. Yang <i>et al.</i> | |
| | | Filing Date: December 10, 2003 | Group: 1616 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|----------------|--------------|---|
| | C332 | Young <i>et al.</i> , "Influence of immunoglobulin heavy and light-chain expression on B-cell differentiation," <i>Genes Develop.</i> , 8:1043-1057, 1994. |
| | C333 | Zakko <i>et al.</i> , "Biliary excretion of Tc- ^{99m} ec in renal studies," <i>Clinical Nuclear Medicine</i> , 23:417-419, 1998. |
| | C334 | Zareneyrizi <i>et al.</i> , "Synthesis of [^{99m} Tc] ethylenedicysteine-colchicine for evaluation of antiangiogenic effect," <i>Anti-Cancer Drugs</i> , 10:685-692, 1999. |

25376238.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.